NASDAQ:ACRX
AcelRx Pharmaceuticals Stock News
$0.86
+0 (+0%)
At Close: Mar 28, 2024
AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2023 Earnings Call Transcript
12:27am, Thursday, 09'th Nov 2023
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Raffi Asadorian - CFO Vince Angotti - CEO Pam Palmer - Chief Medical Offic
AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2023 Earnings Call Transcript
08:16pm, Thursday, 10'th Aug 2023
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Raffi Asadorian – Chief Financial Officer Vince Angotti – Chief Executi
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates
07:01pm, Thursday, 10'th Aug 2023
AcelRx Pharmaceuticals (ACRX) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $1.20 per share a year ago.
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1
07:45pm, Wednesday, 10'th May 2023
AcelRx Pharmaceuticals (ACRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $1.20 per share a year ago.
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates
10:15pm, Thursday, 30'th Mar 2023 Zacks Investment Research
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stoc
AcelRx Pharmaceuticals Inc. (ACRX) Q4 2022 Earnings Call Transcript
08:28pm, Thursday, 30'th Mar 2023
AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX ) Q4 2022 Results Conference Call March 30, 2023 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Of
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates
08:01pm, Thursday, 30'th Mar 2023
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stoc
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023
04:05pm, Tuesday, 21'st Mar 2023
HAYWARD, Calif. , March 21, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapi
AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2022 Results - Earnings Call Transcript
11:09pm, Monday, 14'th Nov 2022
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q3 2022 Results Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief
AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates
10:15pm, Monday, 14'th Nov 2022 Zacks Investment Research
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 21.67% and 7.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto
AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates
06:48pm, Monday, 14'th Nov 2022
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 21.67% and 7.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto
What Happened This Week: Twitter, Tech Wreck And Apple – Earnings Week To Remember
08:45pm, Friday, 28'th Oct 2022 Investing.comWhy Skechers Shares Are Trading Lower; Here Are 25 Stocks Moving Premarket
10:18am, Wednesday, 26'th Oct 2022 Benzinga
Gainers
Ensysce Biosciences, Inc. (NASDAQ: ENSC) rose 53.5% to $0.32 in pre-market trading after gaining 13% on Tuesday.
Cosmos Holdings Inc. (NASDAQ: COSM) shares rose 22.7% to $0.1071 in pre-market
Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket
10:30am, Monday, 17'th Oct 2022 Benzinga
Gainers
Inpixon (NASDAQ: INPX) shares rose 56.7% to $7.49 in pre-market trading after gaining around 10% on Friday. Inpixon reported recent purchase orders of industrial IoT solutions supporting a va
Why Twin Vee Powercats Is Trading Lower By Over 30%; Here Are 30 Stocks Moving Premarket
10:55am, Thursday, 29'th Sep 2022 Benzinga
Gainers
Windtree Therapeutics, Inc (NASDAQ: WINT) rose 50.7% to $0.4827 in pre-market trading after the company said Istaroxime Phase 2 study in early cardiogenic shock was published in the European